{"id":35998,"date":"2025-11-20T13:52:59","date_gmt":"2025-11-20T21:52:59","guid":{"rendered":"https:\/\/getheally.com\/patients\/news\/retatrutide-weight-loss-results-retatutride-vs-tirzepatide-vs-semaglutide-copy"},"modified":"2025-11-25T14:34:33","modified_gmt":"2025-11-25T22:34:33","slug":"what-medication-has-fewer-side-effects-semaglutide-or-tirzepatide-2","status":"publish","type":"post","link":"https:\/\/getheally.com\/patients\/news\/what-medication-has-fewer-side-effects-semaglutide-or-tirzepatide-2","title":{"rendered":"What Medication has Fewer Side Effects, Semaglutide or Tirzepatide?"},"content":{"rendered":"

emaglutide and tirzepatide are two of the most widely used GLP-1\u2013based medications for weight loss and type 2 diabetes management. Both semaglutide and tirzepatide are effective, but they can affect people differently \u2014 especially when it comes to side effects. Understanding how these medications compare can help you choose the option that feels safest and most comfortable for your body.<\/p>\n

Active Ingredient: Semaglutide<\/h4>\n

Semaglutide<\/a> is a GLP-1 receptor agonist only. It mimics the hormone GLP-1, which helps regulate blood sugar and appetite.<\/p>\n

\n
\n\n\n\n\n\n\n\n
Brand Name<\/th>\nManufacturer<\/th>\nRoute<\/th>\nFDA-Approved Use<\/th>\nFDA Approval Year<\/th>\n<\/tr>\n<\/thead>\n
Ozempic<\/a><\/td>\nNovo Nordisk<\/td>\nInjectable (weekly)<\/td>\nType 2 diabetes; Cardiovascular risk reduction<\/td>\n2017<\/td>\n<\/tr>\n
Wegovy<\/a><\/td>\nNovo Nordisk<\/td>\nInjectable (weekly)<\/td>\nChronic weight management<\/td>\n2021<\/td>\n<\/tr>\n
Rybelsus<\/a><\/td>\nNovo Nordisk<\/td>\nOral (daily tablet)<\/td>\nType 2 diabetes<\/td>\n2019<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Throughout this article, any reference to semaglutide for weight loss refers to Wegovy. Mentions of semaglutide for blood sugar control refer to Ozempic.<\/div>\n<\/div>\n<\/div>\n
\n
\n

Active Ingredient: Tirzepatide<\/h4>\n

Tirzepatide<\/a> is a dual agonist \u2014 it activates GLP-1 receptors and<\/em> GIP (glucose-dependent insulinotropic polypeptide) receptors. The added GIP activity may enhance weight loss and blood sugar control compared to GLP-1\u2013only drugs.<\/p>\n

\n
\n\n\n\n\n\n\n
Brand Name<\/th>\nManufacturer<\/th>\nRoute<\/th>\nFDA-Approved Use<\/th>\nFDA Approval Year<\/th>\n<\/tr>\n<\/thead>\n
Mounjaro<\/a><\/td>\nEli Lilly<\/td>\nInjectable (weekly)<\/td>\nType 2 diabetes<\/td>\n2022<\/td>\n<\/tr>\n
Zepbound<\/a><\/td>\nEli Lilly<\/td>\nInjectable (weekly)<\/td>\nChronic weight management<\/td>\n2023<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Throughout this article, any reference to Tirzepatide for weight loss refers to Zepbound. Mentions of Tirzepatide for blood sugar control refer to Mounjaro.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

If you\u2019re unsure which medication is right for you, Heally makes it easy to meet with a licensed provider who can walk you through your symptoms, side effects, and goals.<\/p>\n

Comparing the side effects of semaglutide and tirzepatide<\/h2>\n

Semaglutide (e.g., Ozempic, Wegovy) and tirzepatide (e.g., Zepbound, Mounjaro) work in similar ways, but tirzepatide has dual action \u2014 it activates both GLP-1 and GIP receptors. Because of this, the side effect profiles overlap but are not identical.<\/p>\n

Both medications commonly cause:<\/p>\n